159 related articles for article (PubMed ID: 27920005)
1. Efficacy of Nab-Paclitaxel as Second-line Chemotherapy for Unresectable or Recurrent Gastric Cancer.
Fukuchi M; Mochiki E; Ishiguro T; Ogura T; Sobajima J; Kumagai Y; Ishibashi K; Ishida H
Anticancer Res; 2016 Dec; 36(12):6699-6703. PubMed ID: 27920005
[TBL] [Abstract][Full Text] [Related]
2. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
[TBL] [Abstract][Full Text] [Related]
3. Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial.
Takashima A; Shitara K; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Kimura Y; Amagai K; Fujii H; Muro K; Esaki T; Choda Y; Takano T; Chin K; Sato A; Goto M; Fukushima N; Hara T; Machida N; Ohta M; Boku N; Shimura M; Morita S; Koizumi W
Gastric Cancer; 2019 Jan; 22(1):155-163. PubMed ID: 29855738
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302).
Tamura S; Taniguchi H; Nishikawa K; Imamura H; Fujita J; Takeno A; Matsuyama J; Kimura Y; Kawada J; Hirao M; Hirota M; Fujitani K; Kurokawa Y; Sakai D; Kawakami H; Shimokawa T; Satoh T
Int J Clin Oncol; 2020 Dec; 25(12):2035-2043. PubMed ID: 32926227
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer.
Sasaki Y; Nishina T; Yasui H; Goto M; Muro K; Tsuji A; Koizumi W; Toh Y; Hara T; Miyata Y
Cancer Sci; 2014 Jul; 105(7):812-7. PubMed ID: 24716542
[TBL] [Abstract][Full Text] [Related]
6. [Outcome and Problems of Nab-Paclitaxel Therapy for Gastric Cancer in Clinical Practice].
Doi T; Ishikawa T; Okayama T; Dohi O; Yoshida N; Kamada K; Katada K; Sogame Y; Uchiyama K; Handa O; Takagi T; Yasuda H; Sakagami J; Konishi H; Naito Y; Itoh Y
Gan To Kagaku Ryoho; 2016 Feb; 43(2):211-4. PubMed ID: 27067684
[TBL] [Abstract][Full Text] [Related]
7. [Nanoparticle albumin-bound Paclitaxel for unresectable or recurrent gastric cancer].
Egawa T; Kemmochi T; Nishiya S; Mihara K; Ito Y; Nagashima A
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2251-3. PubMed ID: 25731486
[TBL] [Abstract][Full Text] [Related]
8. Phase II multi-institutional prospective trial of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer refractory to fluoropyrimidine with modified dose reduction criteria (CCOG1303).
Kobayashi D; Mochizuki Y; Torii K; Takeda S; Kawase Y; Ishigure K; Teramoto H; Ando M; Kodera Y
Int J Clin Oncol; 2020 Oct; 25(10):1793-1799. PubMed ID: 32567012
[TBL] [Abstract][Full Text] [Related]
9. Initial Experience with Nab-Paclitaxel for Patients with Advanced Gastric Cancer: Safety and Efficacy.
Kanazawa Y; Fujita I; Kakinuma D; Arai H; Matsuno K; Shimoda T; Ko K; Kato S; Uchida E
Anticancer Res; 2017 May; 37(5):2715-2720. PubMed ID: 28476850
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
Kinoshita J; Fushida S; Tsukada T; Oyama K; Watanabe T; Shoji M; Okamoto K; Nakanuma S; Sakai S; Makino I; Furukawa H; Hayashi H; Nakamura K; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fujimura T; Masakazu Y; Hirakawa K; Ohta T
Oncol Rep; 2014 Jul; 32(1):89-96. PubMed ID: 24859429
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study).
Nakasya A; Hagiwara Y; Ikoma T; Kurioka Y; Matsumoto T; Yamamoto Y; Tsuduki T; Kajiwara T; Moriwaki T; Nishina T; Yamashita N; Hyodo I
Int J Clin Oncol; 2022 Apr; 27(4):684-694. PubMed ID: 35089459
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer.
Takashima T; Kawajiri H; Nishimori T; Tei S; Nishimura S; Yamagata S; Tokunaga S; Mizuyama Y; Sunami T; Tezuka K; Ikeda K; Ogawa Y; Kashiwagi S; Noda S; Onoda N; Ishikawa T; Kudoh S; Takada M; Hirakawa K; Ohira M
Anticancer Res; 2018 Jan; 38(1):379-383. PubMed ID: 29277798
[TBL] [Abstract][Full Text] [Related]
13. Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer.
Okunaka M; Kotani D; Demachi K; Kawazoe A; Yoshino T; Kawasaki T; Shitara K
BMC Cancer; 2020 Nov; 20(1):1111. PubMed ID: 33198652
[TBL] [Abstract][Full Text] [Related]
14. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
[TBL] [Abstract][Full Text] [Related]
15. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
Hersh EM; O'Day SJ; Ribas A; Samlowski WE; Gordon MS; Shechter DE; Clawson AA; Gonzalez R
Cancer; 2010 Jan; 116(1):155-63. PubMed ID: 19877111
[TBL] [Abstract][Full Text] [Related]
16. [Two Cases of Long-Term Control of Advanced Gastric Cancer Treated with>35 Cycles of Low-Dose Nab-Paclitaxel].
Kawaguchi K; Urayama M; Fujimoto H; Isobe H; Fuse A; Ohta K
Gan To Kagaku Ryoho; 2019 Oct; 46(10):1569-1572. PubMed ID: 31631141
[TBL] [Abstract][Full Text] [Related]
17. [Clinical Efficacy and Safety of Nab-Paclitaxel plus Ramucirumab Therapy in Patients with Unresectable Advanced or Recurrent Gastric Cancer].
Murakami K; Takeno A; Masuzawa T; Imada A; Takase K; Toya K; Yukawa Y; Kawai K; Sakamoto T; Katsura Y; Ohmura Y; Kagawa Y; Hata T; Takeda Y; Murata K
Gan To Kagaku Ryoho; 2020 Mar; 47(3):493-495. PubMed ID: 32381926
[TBL] [Abstract][Full Text] [Related]
18. Nab-Paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice.
Aigner J; Marmé F; Smetanay K; Schuetz F; Jaeger D; Schneeweiss A
Anticancer Res; 2013 Aug; 33(8):3407-13. PubMed ID: 23898112
[TBL] [Abstract][Full Text] [Related]
19. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
Dranitsaris G; Coleman R; Gradishar W
Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer.
Hasegawa T; Futamura Y; Horiba A; Yoshida T; Suzuki T; Kato T; Kaito D; Ohno Y; Iida T; Hayashi S; Sawa T
J Radiat Res; 2016 Jan; 57(1):50-4. PubMed ID: 26442970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
